Dermatoprotective activity of a combination of enoxifol with rexod in a reduced form the blood circulation in the skin in diabetes mellitus and hypercholesterinemia

Abstract

Experiments in rats showed that the 9-diethylaminoethyl-2-(3,4-dioxyphenyl)-imidazo- [1,2-a]-benzimidazole dihydrobromide with the provisional name of enoxifol (0.94 - 15 mg/kg), rexod (recombinant human superoxide dismutase; 0.002 mg/kg) and especially their combination in intravenous administration in a reduced blood circulation in the skin against the background of the normoglycemia and hyperglycemia induced by experimental (alloxanic) diabetes mellitus complicated by exogenous hypercholesterinemia have a pronounced dose-dependent dermatoprotective effect, which may be due to the activation of energy processes and increase the reserve capacity of the antioxidant support network and normalization of carbohydrate and lipid metabolism